Valuation: Quest PharmaTech Inc.

Market Cap 3.38M 2.41M 2.11M 1.95M 1.79M 232M 3.46M 23.26M 9.13M 114M 9.06M 8.86M 392M P/E 2025
-3.29x
P/E 2026 1.18x
Enterprise Value 4.37M 3.11M 2.72M 2.51M 2.32M 300M 4.47M 30.04M 11.79M 147M 11.7M 11.44M 506M EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
83.12%
Yield 2025 *
-
Yield 2026 -
Current month-20.00%
1 month-50.00%
3 months-42.86%
6 months-50.00%
Current year-42.86%
1 week 0.02
Extreme 0.02
0.02
1 month 0.02
Extreme 0.02
0.04
Current year 0.02
Extreme 0.02
0.04
1 year 0.02
Extreme 0.02
0.05
3 years 0.02
Extreme 0.015
0.08
5 years 0.02
Extreme 0.015
0.16
10 years 0.02
Extreme 0.015
0.32
Manager TitleAgeSince
Chief Executive Officer - 17/06/2004
Director of Finance/CFO - 01/01/2005
Director TitleAgeSince
Director/Board Member - 17/06/2004
Chairman - 05/07/2021
Director/Board Member - 05/07/2021
Date Insider Type Main position Quantity % Market Cap.
12/12/25 OtherCompany 0 0%
21/10/25 Other

Chief Executive Officer

300,000 0.1774%
21/10/25 Other

Chief Executive Officer

1,000,000 0.5913%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-42.86%-78.95% 2.41M
+3.90%-0.39%+376.72%+599.59% 39.58B
-1.70%+4.46%+7.46%+57.67% 34.69B
-2.01%-0.76%+26.35%-6.83% 34.42B
+0.06%+0.34%+2.32%+29.30% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+68.48%+117.39% 15.36B
+1.12%+1.91%+15.90%+19.65% 14.05B
0.00%+1.36%+15.74%-30.62% 13.02B
-0.08%-3.01%+1,271.69%+649.69% 11.76B
Average +0.17%+0.03%+193.53%+150.76% 20.62B
Weighted average by Cap. +0.24%+0.36%+171.43%+187.42%

Financials

2025 2026
Net sales - -
Net income -1.8M -1.28M -1.12M -1.04M -955K -124M -1.84M -12.39M -4.86M -60.59M -4.82M -4.72M -209M 5M 3.56M 3.12M 2.87M 2.65M 343M 5.11M 34.37M 13.49M 168M 13.39M 13.09M 579M
Net Debt 795K 567K 496K 457K 421K 54.58M 813K 5.47M 2.15M 26.74M 2.13M 2.08M 92.05M 986K 702K 615K 567K 523K 67.67M 1.01M 6.78M 2.66M 33.16M 2.64M 2.58M 114M
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-
Date Price Change Volume
17/07/26 CA$0.0200 0.00% 2,000
16/07/26 CA$0.0200 -20.00% 2,250
14/07/26 CA$0.0250 +25.00% 19,600
10/07/26 CA$0.0200 -20.00% 155,100